Literature DB >> 8803647

Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists.

D A Revicki1, A Shakespeare, P Kind.   

Abstract

Health state preferences are important for evaluating the outcomes of medical treatment. This study examined preferences of patients for schizophrenia-related health states and compares patient preferences with those of caregivers and psychiatrists. Health-state descriptions were developed for five different outcomes likely to be experienced by schizophrenic patients. Forty-nine schizophrenic patients and their primary caregiver assigned preferences to the hypothetical states and the patient's current state using categorical rating scales and paired comparisons; physicians rated the states using the standard gamble and categorical rating scale. Mean standard gamble utilities for the patient's current health were 0.75, and ranged from 0.56 for the inpatient state to 0.83 for excellent function, outpatient. Mean categorical rating scale preferences for the patient's current health state were 0.67 for patients, 0.66 for caregivers and 0.66 for clinicians. Patient preferences were comparable with clinician and caregiver preferences for hypothetical health states. Patient preferences were correlated with clinician and caregiver preferences for current health. It was concluded that schizophrenic patients are able to complete categorical rating scales and paired comparisons, and patient preferences are associated with clinician and caregiver preferences.

Entities:  

Mesh:

Year:  1996        PMID: 8803647

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  14 in total

Review 1.  A review and critique of studies reporting utility values for schizophrenia-related health states.

Authors:  Ifigeneia Mavranezouli
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Authors:  R Rosenheck; J Cramer; W Xu; J Grabowski; R Douyon; J Thomas; W Henderson; D Charney
Journal:  Health Serv Res       Date:  1998-12       Impact factor: 3.402

3.  A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia.

Authors:  John F P Bridges; Lara Slawik; Annette Schmeding; Jens Reimer; Dieter Naber; Olaf Kuhnigk
Journal:  Health Expect       Date:  2011-06-14       Impact factor: 3.377

4.  Measuring preferences for schizophrenia outcomes with the time tradeoff method.

Authors:  Martha Shumway; Tandy L Chouljian; Cynthia L Battle
Journal:  J Behav Health Serv Res       Date:  2005 Jan-Mar       Impact factor: 1.505

5.  Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

Authors:  D A Revicki; L A Genduso; S H Hamilton; D Ganoczy; C M Beasley
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

6.  Assessing health utilities in schizophrenia. A feasibility study.

Authors:  L N Voruganti; A G Awad; L K Oyewumi; L Cortese; S Zirul; R Dhawan
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

Review 7.  Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.

Authors:  D A Revicki
Journal:  J Psychiatry Neurosci       Date:  1997-07       Impact factor: 6.186

8.  How bad is depression? Preference score estimates from depressed patients and the general population.

Authors:  Jeffrey M Pyne; John C Fortney; Shanti Tripathi; David Feeny; Peter Ubel; John Brazier
Journal:  Health Serv Res       Date:  2009-04-21       Impact factor: 3.402

9.  When there is too much to do: how practicing physicians prioritize among recommended interventions.

Authors:  Timothy P Hofer; Judith K Zemencuk; Rodney A Hayward
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

10.  Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.

Authors:  Thomas R Einarson; Maria Geitona; Alexandros Chaidemenos; Vasiliki Karpouza; Theodoros Mougiakos; Periklis Paterakis; Dimitrios Ploumpidis; Dionyssios Potamitis-Komis; Roman Zilbershtein; Colin Vicente; Charles Piwko; Panagiotis Kakkavas; Konstantina Paparouni; Rasmus C D Jensen; Michiel E H Hemels
Journal:  Ann Gen Psychiatry       Date:  2012-07-02       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.